A case of haemolytic disease of the fetus and newborn attributed to a novel antigen in the RHAG blood group system
Vox Sanguinis · 2023-12 · 118 (12) · 1095-1099
DOI: 10.1111/vox.13536 ↗Kurz gefasst
Fallbericht in der Zeitschrift Vox Sanguinis, online erschienen am 14.12.2023. Verfasst von Saion Chatterjee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Services and Research, Australian Red Cross Lifeblood, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Blood Group Antigens, Hematologic Diseases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and Objectives A newborn presented with jaundice in Thailand. The cord red cells tested positive by direct antiglobulin test (DAT) for an unknown maternal red cell antibody. Initial blood group sequencing suggested that the infant carried a novel variant RHAG c.140T>C , responsible for a low‐prevalence antigen in the RHAG blood group system (ISBT 030). We report here on testing of samples from the infant's parents and older sibling to define a new antigen in the RHAG system. Materials and Methods Massive parallel sequencing (MPS) using a custom‐designed panel was performed on all four family members. Extended serological testing was also performed to determine whether family members with the same variant as the infant showed reactivity with the antibody in the maternal plasma.
Results
We identified a novel single nucleotide variant (SNV) ( RHAG c.140T>C , p.[Phe47Ser]) in samples from three of the four family members tested (the infant, the older sibling and the father). The variant was not detected in the mother's sample. Maternal plasma showed positive agglutination with all family members tested; however, when tested with routine panel cells, no reactivity was observed.
Conclusion
This case study showed that the presence of the novel variant ( RHAG c.140T>C ), encoding a p.(Phe47Ser) change in the RhAG glycoprotein, was the apparent cause of incompatibility between maternal plasma and that of red cells from the proband, father and older sibling of the proband. We propose this variant to be a new low‐prevalence antigen in the RHAG blood group system.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Services and Research, Australian Red Cross Lifeblood, Brisbane, Queensland, Australia.
- Blood Bank, Faculty of Medicine, Ramathibodi Hospital, Bangkok, Thailand.
ORCID-Profile: Saion Chatterjee, Yew-Wah Liew
Zitieren
APA
Chatterjee, S., Millard, G., Chiawchan, S., Chanthet, S., Daly, J., Hyland, C., Kitpoka, P., Powley, T., & Liew, Y. W. (2023). A case of haemolytic disease of the fetus and newborn attributed to a novel antigen in the RHAG blood group system. Vox Sanguinis, 118(12), 1095-1099. https://doi.org/10.1111/vox.13536
Vancouver
Chatterjee S, Millard G, Chiawchan S, Chanthet S, Daly J, Hyland C, et al. A case of haemolytic disease of the fetus and newborn attributed to a novel antigen in the RHAG blood group system. Vox Sanguinis. 2023;118(12):1095-1099. doi:10.1111/vox.13536
BibTeX
@article{Chatterjee2023,
author = {Chatterjee, Saion and Millard, Glenda and Chiawchan, Suwat and Chanthet, Sarawan and Daly, James and Hyland, Catherine and Kitpoka, Pimpin and Powley, Tanya and Liew, Yew-Wah},
title = {A case of haemolytic disease of the fetus and newborn attributed to a novel antigen in the RHAG blood group system},
journal = {Vox Sanguinis},
year = {2023},
volume = {118},
number = {12},
pages = {1095--1099},
doi = {10.1111/vox.13536}
}
EUVIMED